Hansoh Pharma Overhauls Equity Incentives With New 2026 Share Scheme

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has issued an update.

Hansoh Pharmaceutical Group has moved to overhaul its equity incentive framework by terminating its existing post-IPO restricted share unit scheme, originally adopted in 2019 and valid for ten years, ahead of schedule. Awards already granted under the old plan will remain valid and continue to vest, but no new grants will be made once the new structure takes effect.

The board is seeking shareholder approval at the upcoming annual general meeting for a new 2026 share scheme that introduces both RSUs and share options funded by new, existing, and treasury shares, in line with updated Hong Kong listing rules. The revamped plan is aimed at better aligning with market practice while enhancing talent retention and attraction, tying employee incentives more closely to shareholder value and the group’s long-term growth objectives.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a China-based biopharmaceutical company listed in Hong Kong that develops, manufactures, and markets innovative and generic medicines. The group focuses on therapeutic areas such as oncology, central nervous system diseases, anti-infectives, and other high-demand segments in the Chinese and international pharmaceutical markets.

Average Trading Volume: 9,534,243

Technical Sentiment Signal: Buy

Current Market Cap: HK$238.7B

For detailed information about 3692 stock, go to TipRanks’ Stock Analysis page.